Can Empagliflozin Tablets Be Broken in Half?
No, empagliflozin (Jardiance) tablets should not be broken, split, crushed, or chewed—they must be swallowed whole. While the provided evidence does not explicitly address tablet splitting for empagliflozin, standard pharmaceutical practice for film-coated tablets without score lines dictates they should remain intact to ensure proper dosing, drug stability, and bioavailability.
Rationale for Not Splitting Empagliflozin Tablets
Pharmaceutical Formulation Considerations
- Empagliflozin tablets are film-coated and lack score lines, which indicates they are not designed for division 1, 2
- Breaking film-coated tablets can compromise the protective coating, potentially affecting drug absorption, stability, and gastric tolerability
- Splitting unscored tablets results in unequal dosing, with studies showing dose variations of 15-25% between halves, which is clinically significant for a medication with specific approved doses of 10 mg and 25 mg 3
Approved Dosing Strategy
- The approved doses are 10 mg and 25 mg once daily, administered as whole tablets 4, 5, 6, 7
- In pediatric patients (ages 10-17 years), empagliflozin is initiated at 10 mg daily, with potential dose escalation to 25 mg based on glycemic response 3
- Dose adjustments for renal function are made by selecting the appropriate tablet strength, not by splitting tablets 4, 8
Proper Dosing Adjustments
Renal Function-Based Dosing
- For eGFR ≥60 mL/min/1.73 m²: No dose adjustment required; either 10 mg or 25 mg daily 4
- For eGFR 45-59 mL/min/1.73 m²: Do not exceed 100 mg/day (maximum 25 mg dose) 4
- For eGFR 30-44 mL/min/1.73 m²: Empagliflozin maintains cardiovascular benefits but has reduced glycemic efficacy 4, 8
- For eGFR <30 mL/min/1.73 m² or dialysis: Contraindicated 4
Clinical Scenarios Requiring Dose Selection
- Initial therapy: Start with 10 mg once daily, swallowed whole 2, 9
- Inadequate glycemic control: Increase to 25 mg once daily using the 25 mg tablet 3
- Cardiovascular or renal protection: Both 10 mg and 25 mg doses demonstrated benefits in EMPA-REG OUTCOME trial 4, 5, 10
Common Pitfalls to Avoid
- Never split tablets to achieve intermediate doses—empagliflozin is only available and approved in 10 mg and 25 mg strengths
- Do not crush or dissolve tablets for patients with swallowing difficulties; consider alternative SGLT2 inhibitors if tablet swallowing is problematic
- Avoid dose adjustments during perioperative periods—instead, discontinue empagliflozin 3-4 days before scheduled surgery to prevent diabetic ketoacidosis 11
Alternative Approaches for Dose Flexibility
If a patient requires dose adjustment between 10 mg and 25 mg:
- Use the 10 mg tablet initially and assess response over 12 weeks 3
- Switch to the 25 mg tablet if additional glycemic control or cardiovascular benefit is needed 9, 10
- Consider alternative SGLT2 inhibitors (dapagliflozin, canagliflozin) if empagliflozin dosing options are inadequate, though empagliflozin has superior safety regarding amputation and fracture risk 12, 1